Accuray Hires Chief Commercial Officer

SUNNYVALE, Calif., Sept. 21, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that Kelly Londy has joined Accuray as Senior Vice President and Chief Commercial Officer, effective October 1, 2011.

Londy has spent her career working in the medical device field, serving in leadership roles for major medical capital equipment companies General Electric (GE) Healthcare and Philips Healthcare. She brings more than 20 years of strategic business, sales and marketing experience in the medical device field, coupled with nine years of practical, clinical experience in radiography. Londy's core strengths include building markets for emerging technologies, and cross-functional team building with specific experience in post-acquisition integration.

Before joining Accuray, Londy served as Vice President and General Manager of Molecular Imaging at GE Healthcare North America. There she optimized multi-business strategy with a focus on value proposition for improved cost, quality and access to new technologies. Prior to this role at GE Healthcare, she spent seven years at Philips Healthcare North America where she served as Vice President and General Manager of the company's Computed Tomography (CT), Nuclear Medicine, Positron Emission Tomography (PET) and Oncology business lines. Former roles at Philips included Vice President of Strategic Business, Corporate Accounts and Government Businesses. Prior to joining Philips, Londy served in various sales and marketing roles at GE Healthcare within their Women's Health Care and MRI business lines. Londy began her career as a radiographer at the University of Michigan, where she also managed the Women's Health Center.

"We are extremely excited to have Kelly join our executive team, and are confident that her understanding of the healthcare environment and her extensive knowledge of capital equipment's role within it will help us drive demand for CyberKnife and TomoTherapy Systems," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "Kelly's successful track record operating at companies the scale of where Accuray is headed, following our recent acquisition of TomoTherapy, will help to ensure a strong, integrated global presence and operational effectiveness."

"I am looking forward to joining Accuray at such an exciting time in the company's history," said Londy. "This role allows me to leverage my expertise in growing markets and my passion for improving patient care to help Accuray build a strong global presence and extend the reach of its life-saving technologies."

In her role, Londy will report to Accuray's president and chief executive officer Euan Thomson, with Accuray's regional general managers reporting to her. Londy will also oversee Global Strategic Marketing (GSM). She will be responsible for developing and managing the global commercial function and driving strategic sales and marketing initiatives.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 575 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements market opportunity and scale are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products, clinical benefits and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year filed on September 19, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated